Limited utility of oral glucose tolerance test in biochemically active acromegaly

European Journal of Endocrinology

Volumn 164, Issue 1, 2011, Pages 17-22

  Ribeiro Oliveira Jr , Anton̂io ^a   Faje, Alexander T ^b   Barkan, Ariel L ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HORMONE DETERMINATION; MEASUREMENT; RELIABILITY; SCORING SYSTEM;

ACROMEGALY; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; FALSE NEGATIVE REACTIONS; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS;

EID: 78751493190     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0744     Document Type: Article

References (31)

1. Acromegaly Therapy Consensus Development Panel. Consensus statement: benefits versus risks of medical therapy for acromegaly. American Journal of Medicine 1994 97 468-473. (doi:10.1016/ 0002-9343(94)90327-1)
2. Freda PU, Post KD, Powell JS & Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3808-3816. (doi:10.1210/jc.83.11.3808)
3. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE & Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. Journal of Clinical Endocrinology and Metabolism 2004 89 495-500. (doi:10.1210/jc.2003-031316)
4. Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A & Arosio M. Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. Journal of Clinical Endocrinology and Metabolism 2005 90 1377-1382. (doi:10.1210/jc.2004-1974)
5. Ronchi CL, Arosio M, Rizzo E, Lania AG, Beck-Peccoz P & Spada A. Adequacy of current postglucose GH nadir limit (<1 microg/l) to define long-lasting remission of acromegalic disease. Clinical Endocrinology 2007 66 538-542.
6. Dimaraki EV, Jaffe CA, Mott-Friberg R, Chandler WF & Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. Journal of Clinical Endocrinology and Metabolism 2002 87 3537-3542. (doi:10.1210/jc.87.8.3537)
7. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529. (doi:10.1210/jc.85.2.526)
8. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S & Acromegaly Consensus Group . A consensus on criteria for cure of acromegaly. Journal of Clinical Endocrinology and Metabolism 2010 95 3141-3148. (doi:10.1210/jc.2009-2670)
9. Rosário PW & Furtado MS. Growth hormone after oral glucose overload: revision of reference values in normal subjects. Arquivos Brasileiros de Endocrinologia e Metabologia 2008 52 1139-1144.
10. Brabant G, Von Zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A,Wilde J, Schemer R & Kann P. Seruminsulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Hormone Research 2003 60 53-60. (doi:10.1159/000071871)
11. Krebs A, Wallaschofski H, Spilcke-Liss E, Kohlmann T, Brabant G, Völzke H & Nauck M. Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population. Clinical Chemistry and Laboratory Medicine 2008 46 1776-1783. (doi:10.1515/CCLM.2008.349)
12. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2010 33 S11-S61. (doi:10.2337/dc10-S011)
13. Costa AC, Rossi A, Martinelli CE Jr, Machado HR & Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure? Journal of Clinical Endocrinology and Metabolism 2002 87 3142-3147. (doi:10.1210/jc.87.7.3142)
14. Cazabat L, Souberbielle JC & Chanson P. Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly. Pituitary 2008 11 129-139. (doi:10.1007/s11102-008-0113-7)
15. Gullu S, Keles H, Delibasi T, Tonyukuk V, Kamel N & Erdogan G. Remission criteria for the follow-up of patients with acromegaly. European Journal of Endocrinology 2004 150 465-471. (doi:10.1530/eje.0.1500465)
16. Serri O, Beauregard C & Hardy J. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2004 89 658-661. (doi:10.1210/jc.2003- 030915)
17. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schofl C & Pfeiffer AF. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. Journal of Clinical Endocrinology and Metabolism 2008 93 1254-1262. (doi:10.1210/jc.2007-2084)
18. Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P & Lombardi G. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clinical Endocrinology 2006 65 250-256. (doi:10.1111/j.1365-2265.2006.02584.x)
19. Elias PC, Lugao HB, Pereira MC, Machado HR, Castro M & Moreira AC. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. Hormone and Metabolic Research 2010 42 50-55. (doi:10.1055/s-0029-1239522)
20. Karavitaki N, Fernandez A, Fazal-Sanderson V & Wass JA. The value of the oral glucose tolerance test, random serum growth hormone and mean growth hormone levels in assessing the postoperative outcome of patients with acromegaly. Clinical Endocrinology 2009 71 840-845. (doi:10.1111/j.1365-2265. 2009.03578.x)
21. Machado EO, Taboada GF, Neto LV, van Haute FR, Corrêa LL, Balarini GA, Shrank Y, Goulart M & Gadelha MR. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Hormone & IGF Research 2008 18 389-393. (doi:10.1016/j.ghir.2008.02.001)
22. Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, Ferone D & Barreca A. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clinical Endocrinology 2004 61 138-144. (doi:10.1111/j.1365-2265.2004.02064.x)
23. Carmichael JD, Bonert VS, Mirocha JM & Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2009 94 523-527. (doi:10.1210/jc.2008-1371)
24. Espinosa-de-Los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G, Mendoza V, Hernández I, Molina M & Mercado M. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease status. Clinical Endocrinology 2006 64 245-249. (doi:10.1111/j.1365-2265.2006.02430.x)
25. Faje AT & Barkan AL. Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. Journal of Clinical Endocrinology and Metabolism 2010 95 2486-2491. (doi:10.1210/jc.2009-2634)
26. Surya S, Horowitz JF, Goldenberg N, Sakharova A, Harber M, Cornford AS, Symons K & Barkan AL. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. Journal of Clinical Endocrinology and Metabolism 2009 94 2828-2834. (doi:10.1210/jc.2009-0638)
27. Puder JJ, Nilavar S, Post KD & Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1972-1978. (doi:10.1210/jc.2004-2009)
28. Sherlock M, Aragon AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A & Stewart PM. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clinical Endocrinology 2009 71 74-81. (doi:10.1111/j.1365-2265.2008.03461.x)
29. Barkan AL, Beitins IZ & Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. Journal of Clinical Endocrinology and Metabolism 1988 67 69-73. (doi:10.1210/jcem-67-1-69)
30. Granada ML, Sanmartí A, Lucas A, Salinas I, Carrascosa A, Foz M & Audí L. Assay-dependent results of immunoassayable spontaneous 24-hour growth hormone secretion in short children. Acta Paediatrica Scandinavica. Supplement 1990 370 63-70. (doi:10.1111/j.1651-2227.1990.tb11675. x)
31. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE & Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clinical Endocrinology 2007 67 65-70. (doi:10.1111/j.1365-2265.2007.02836.x) (Pubitemid 46955441)